Open-label, randomized comparison of itraconazole versus caspofungin for prophylaxis in patients with hematologic malignancies

Antimicrobial Agents and Chemotherapy

Volumn 50, Issue 1, 2006, Pages 143-147

  Mattiuzzi, Gloria N ^a   Alvarado, Gladys ^a   Giles, Francis J ^a   Ostrosky Zeichner, Luis ^b   Cortes, Jorge ^a   O'Brien, Susan ^a   Verstovsek, Srdan ^a   Faderl, Stefan ^a   Zhou, Xian ^a   Raad, Issam I ^a   Bekele, B Nebiyou ^a   Leitz, G J ^c   Lopez Roman, Ivonne ^a   Estey, Elihu H ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^c Ortho Biotech Products LP   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; ANTIVIRUS AGENT; CASPOFUNGIN; CYTARABINE; FLUDARABINE; GEMTUZUMAB OZOGAMICIN; IDARUBICIN; ITRACONAZOLE; LEVOFLOXACIN; TOPOTECAN;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LEUKEMIA; ADOLESCENT; ADULT; ARTICLE; ASPERGILLUS; CANCER CHEMOTHERAPY; CANDIDA; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEMATOLOGIC MALIGNANCY; HUMAN; HYPERBILIRUBINEMIA; MAJOR CLINICAL STUDY; MALE; MYCOSIS; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL; PROGNOSIS; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL;

ADOLESCENT; ADULT; AGED; ANTIFUNGAL AGENTS; ANTINEOPLASTIC AGENTS; FEMALE; HEMATOLOGIC NEOPLASMS; HUMANS; ITRACONAZOLE; MALE; MIDDLE AGED; PEPTIDES, CYCLIC; SAFETY; TREATMENT OUTCOME;

EID: 29944444166     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.50.1.143-147.2006     Document Type: Article

References (24)

1. Ahmad, S. R., S. J. Singer, and B. G. Leissa. 2001. Congestive heart failure associated with itraconazole. Lancet 357:1766-1767.
2. Ascioglu, S., J. H. Rex, B. de Pauw, J. E. Bennett, J. Bille, F. Crokaert, D. W. Denning, J. P. Donnelly, J. E. Edwards, Z. Erjavec, D. Fiere, O. Lortholary, J. Maertens, J. F. Meis, T. F. Patterson, J. Ritter, D. Selleslag, P. M. Shah, D. A. Stevens, T. J. Walsh, and Invasive Fungal Infections Cooperative Group of the European Organization for Research and Treatment of Cancer Mycoses Study Group of the National Institute of Allergy and Infectious Diseases. 2002. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin. Infect. Dis. 34:7-14.
3. Becker, R. A., J. M. Chambers, and A. R. Wilks. 1988. The new S language. Wadsworth, Pacific Grove, Calif.
4. 3a. Clinical and Laboratory Standards Institute. 2002. Reference method for broth dilution, antifungal susceptibility testing of yeasts. Document M27-A2. Clinical and Laboratory Standards Institute, Wayne, Pa.
5. Cox, D. R. 1972. Regression models and life tables. J. R Stat. Soc. 34:187-220.
6. Denning, D. W. 2003. Echinocandin antifungal drugs. Lancet 362:1142-1151.
7. Espinel-Ingroff, A. 1998. Comparison of in vitro activities of the new triazole SCH56592 and the echinocandins MK-0991 (L-743,872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeasts. J. Clin. Microbiol. 36:2950-2956.
8. Glasmacher, A., A. Prentice, M. Gorschluter, S. Engelhart, C. Hahn, B. Djulbegovic, and I. G. Schmidt-Wolf. 2003. Itraconazole prevents invasive fungal infections in ncutropenic patients treated for hematologic malignancies: evidence from a meta-analysis of 3,597 patients. J. Clin. Oncol. 21:4615-4626.
9. Goodman, D., E. Pamer, A. Jakubowski, C. Morris, and K. Sepkowitz. 2002. Breakthrough trichosporonosis in a bone marrow transplant recipient receiving caspofungin acetate. Clin. Infect. Dis. 35:E35-E36.
10. 8a. Harrell, F. E., Jr., and Y. C. Shih. 2001. Using full probability models to compute probabilities of actual interest to decision makers. Int. J. Technol. Assess. Health Care 17:17-26.
11. Hosmer, D. W., and S. Lemeshow. 1999. Applied survival analysis. Wiley, New York, N.Y.
12. Kaplan, E. L., and P. Meier. 1958. Nonparametric estimations from incomplete observations. J. Am. Stat. Assoc. 53:457-481.
13. Keating, G. M., and B. Jarvis. 2001. Caspofungin. Drugs 61:1121-1129.
14. Mattiuzzi, G., G. Alvarado, R. Alvarez, et al. 2003. Causes of death in patients with acute myelogenous leukemia and high-risk myelodysplastic syndrome undergoing induction chemotherapy. Blood 102:878a.
15. Mattiuzzi, G. N., E. Estey, I. Raad, F. Giles, J. Cortes, Y. Shen, D. Kontoyiannis, C. Koller, M. Munsell, M. Beran, and H. Kantarjian. 2003. Liposomal amphotericin B versus the combination of fluconazole and itraconazole as prophylaxis for invasive fungal infections during induction chemotherapy for acute myelogenous leukemia and myelodysplastic syndrome. Cancer 97:450-456.
16. Mattiuzzi, G. N., H. Kantarjian, S. Faderl, J. Lim, D. Kontoyiannis, D. Thomas, W. Wierda, I. Raad, G. Garcia-Manero, X. Zhou, A. Ferrajoli, N. Bekele, and E. Estey. 2004. Amphotericin B lipid complex as prophylaxis of invasive fungal infections in patients with acute myelogenous leukemia and myelodysplastic syndrome undergoing induction chemotherapy. Cancer 100:581-589.
17. Mattiuzzi, G. N., H. M. Kantarjian, S. O'Brien, D. P. Kontoyiannis, F. Giles, X. Zhou, J. Lim, B. N. Bekele, S. Faderl, J. Cortes, S. Pierce, G. J. Leitz, I. Raad, and E. Estey. 2004. Intravenous itraconazole for prophylaxis of systemic fungal infections in patients with acute myelogenous leukemia and high-risk myelodysplastic syndrome undergoing induction chemotherapy. Cancer 100:568-573.
18. Mora-Duarte, J., R. Betts, C. Rotstein, A. L. Colombo, L. Thompson-Moya, J. Smietana, R. Lupinacci, C. Sable, N. Kartsonis, J. Perfect, and Caspofungin Invasive Candidiasis Study Group. 2002. Comparison of caspofungin and amphotericin B for invasive Candidiasis. N. Engl. J. Med. 347:2020-2029.
19. Ostrosky-Zeichner, L., J. H. Rex, P. G. Pappas, R. J. Hamill, R. A. Larsen, H. W. Horowitz, W. G. Powderly, N. Hyslop, C. A. Kauffman, J. Cleary, J. E. Mangino, and J. Lee. 2003. Antifungal susceptibility survey of 2,000 blood-stream Candida isolates in the United States. Antimicrob. Agents Chemother. 47:3149-3154.
20. Pocock, S. J., and R. Simon. 1975. Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial. Biometrics 31:103-115.
21. Rex, J. H., E. J. Anaissie, E. Boutati, E. Estey, and H. J. Kantarjian. 2002. Systemic antifungal prophylaxis reduces invasive fungal infections in acute myelogenous leukemia: a retrospective review of 833 episodes of neutropenia in 322 adults. Leukemia 16:1197-1203.
22. Sable, C. A., B. Y. Nguyen, J. A. Chodakewitz, and M. J. DiNubile. 2002. Safety and tolcrability of caspofungin acetate in the treatment of fungal infections. Transplant. Infect. Dis. 4:25-30.
23. Snedecor, G. W., and W. G. Cochran. 1980. Statistical methods, 7th ed. Iowa State University Press, Ames, Iowa.
24. Uzun, O., S. Kocagoz, Y. Cetinkaya, S. Arikan, and S. Unal. 1997. In vitro activity of a new echinocandin, LY303366, compared with those of amphotericin B and fluconazole against clinical yeast isolates. Antimicrob. Agents Chemother. 41:1156-1157.